Cardiac Radionuclide Imaging

LCD Information Document Information Source LCD ID N/A LCD ID L33457 Original ICD-9 LCD ID Not Applicable LCD Title Cardiac Radionuclide Imaging Proposed LCD in Comment Period N/A Source Proposed LCD N/A Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 03/23/2023 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date N/A Notice Period End Date N/A CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity. Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Title XVIII of the Social Security Act, §1862(a)(1)(A) allows coverage and payment for only those services that are considered to be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.Title XVIII of the Social Security Act, §1862(a)(7) excludes routine physical examinations.CMS Internet-Only Manual, Pub. 100-03, Medicare National Coverage Determinations (NCD) Manual, Chapter 1, Part 4, §220.6.1 PET for Perfusion of the Heart (Various Effective Dates) and §220.12 Single Photon Emission Computed Tomograph (SPECT) Coverage Indications, Limitations, and/or Medical Necessity The 2 types of radionuclide studies commonly used for cardiac evaluation are myocardial perfusion imaging (MPI) and cardiac blood pool imaging (multiple gated acquisition scanning (MUGA), ventriculography). MPI is used primarily for the evaluation of coronary artery disease (CAD). Ventriculography is sometimes referred to as MUGA or cardiac blood pool imaging and is primarily used to evaluate valvular disease and cardiomyopathies. Either type of study may be obtained at rest or with stress. Stress may be provided by exercise or with pharmacologic agents.MPI is a diagnostic procedure that evaluates blood flow to cardiac muscle using radionuclides. A gamma camera is used to record images in planar or tomographic (single photon emission computed tomography (SPECT)) projections. Use of dual radiopharmaceuticals permit concurrent studies at rest and after stress, which are then compared and interpreted by a nuclear physician. Since the radiopharmaceutical accumulates in the myocardium in relation to blood flow, ischemic and infarcted myocardium can be detected. With the use of technetium based radiopharmaceuticals, the perfusion imaging may be linked to acquisition of “first pass” data to visualize blood flow through the right heart, lungs and left heart giving diagnostically useful information about cardiac chamber shunts, wall motion, cardiac output, ejection fraction (EF), left ventricular volume, shunt fraction and valvular regurgitation. Positron emission tomography (PET) scans performed for the diagnosis and management of patients with known or suspected CAD, using the Food and Drug Administration (FDA) approved Rubidium 82 (Rb 82) Opens in a new window, are covered when the following conditions are met: The PET scan (at rest or rest with stress) is performed in place of SPECT; or Is performed following an inconclusive SPECT (results that are equivocal, technically uninterpretable, or discordant with the patient’s other clinical data). In such cases, the PET scan must have been determined to be medically necessary to guide further treatment of the patient. When a PET scan is performed as an additional diagnostic test in the instance of an equivocal SPECT, the reason for performing the PET scan must be clearly documented in the patient’s record. The following studies are considered investigational and will not be covered: Ambulatory radionuclide cardiac monitoring Monoclonal anti-myosin imaging Radionuclide imaging of thrombi Radionuclide imaging of cardiac adrenergic nerves Myocardial Perfusion ImagingPatients with a high pretest probability of disease are usually not candidates for this study unless determination of the size and reversibility of a defect are required for clinical decision making. Patients whose diagnosis is in question benefit most from this study. Patients with a low pretest probability of disease are usually not studied except when a prior exercise stress test by treadmill electrocardiogram (ECG) or echocardiogram (echo) is a presumed false positive. Stress MPI, preceded by satisfactory stress echo, is not medically necessary. Indications for Myocardial Perfusion Imaging 1. Acute myocardial infarction (AMI) - MPI is not typically performed during the acute period of myocardial infarction (MI), if the diagnosis is established by other means. In selected patients, imaging is appropriate in the assessment of: Disease severity Risk assessment and/or prognosis Efficacy of acute reperfusion therapy Evidence of myocardial salvage Suspected infarction when the combination of history and other tests is not diagnostic 2. Unstable angina - MPI may be useful as an adjunct to other tests in the diagnosis or treatment of unstable angina only when the combination of history and other tests is not diagnostic. In selected patients, imaging is appropriate for: Identification of ischemia in the distribution of a known lesion or in remote areas Identification of the severity/extent of disease in patients with medically unstable angina or ongoing ischemia Measurement of left ventricular function (LVF) 3. Chronic ischemic heart disease - The use of MPI is well established in the diagnosis and management of CAD and is covered in these situations: Diagnosis of CAD, especially in patients with atypical chest pain Evaluation of abnormal or suspected false positive stress ECG Evaluation of other symptoms suspicious for the diagnosis of CAD such as syncope and ventricular arrhythmia Assessment of myocardial viability after revascularization or medical management Planning percutaneous transluminal coronary angioplasty (PTCA) to identify lesions causing ischemia, if unknown Evaluation of suspected or known CAD prior to high risk surgical procedure Identification of the presence, location, extent, and severity of myocardial ischemia Assessment of drug therapy Assessment of symptoms suggesting restenosis following PTCA Assessment of symptoms suggesting ischemia following coronary artery bypass graft (CABG) Follow up of symptomatic ischemic heart disease 4. Congenital heart disease (CHD) - Echo is the method of choice for evaluating patients with known or suspected CHD. Selected patients may benefit from MPI when assessing for: Diagnosis of anomalies of the coronary circulation Kawasaki’s disease 5. Post-transplant cardiac disease Assessment of coronary arteriopathy Evaluation for ventricular dysfunction with post-transplant rejection Cardiac Blood Pool Imaging (MUGA, Ventriculography)These services are allowed for the evaluation of ventricular size, wall motion, stroke volume, and EF when this information is medically necessary to direct further evaluation and management of the cardiac condition. Indications for Cardiac Blood Pool Imaging (MUGA, Ventriculography) 1. Cardiomyopathy - Cardiac blood pool imaging (MUGA, ventriculography) is covered for: Diagnosis of hypertrophic cardiomyopathy and/or myocardial ischemia Differentiation of ischemic from non-ischemic cardiomyopathy 2. Post-transplant cardiac disease Assessment of coronary arteriopathy Evaluation for ventricular dysfunction with post-transplant rejection 3. Assessment of cardiac function for cardiotoxic chemotherapy A. One baseline study is considered medically necessary prior to the initiation of cardiotoxic chemotherapy when 1 of the following conditions is met: 1. No echo is planned or performed 2. Prior echo is uninterpretable due to poor visualization window B. Cardiac function monitoring during or at the completion of cardiotoxic chemotherapy. Cardiotoxic chemotherapy includes any of the following medications: · 5-FU (5 fluorouracil) · Adriamycin® (doxorubicin) · Avastin® (bevacizumab) · Cerubidine® (daunorubicin) · Clolar® (clofarabine) · Cytoxan® (cyclophosphamide) · Epirubicin (Pharmorubicin®) · Gleevec® (imatinib) · Herceptin® (trastuzumab) · Ifex® (ifosfamide) · Mutamycin® (mitomycin) · Nexavar® (sorafenib) · Novantrone® (mitoxantrone) · Sutent® (sunitinib) · Taxol® (paclitaxel) · Taxotere® (docetaxel) · Tykerb® (lapatinib) · Valstar® (valrubicin) · Xeloda® (capecitabine) · Zavedos® (idarubicin) Pharmacologic Stress AgentsFor those patients who are unable to reach 75-100% of their age predicted maximum heart rate by physiologic exercise, vasodilation can be achieved with the use of either dipyridamole or adenosine. Use of pharmacologic agents in MPI is not a standard of care and is not medically necessary unless exercise is not possible. In some cases dobutamine may be used to effect stress through its inotropic effect. 1. Dipyridamole is typically administered intravenously (IV) at 0.57 mg/kg over a 4-minute period. The maximum dose should not exceed 60 mg. Since the dilation effect persists, after injection of the radiopharmaceutical, its effect is typically reversed with IV aminophylline, which must be available to reverse ischemia when it occurs. Dipyridamole is relatively contraindicated in patients with: Known bronchospastic lung disease (asthma) Systemic hypotension (systolic blood pressure (BP) below 100 mm Hg.) AMI less than 48 hours old Unstable angina 2. Adenosine is administered IV at 0.14 mg/kg/min over 6 minutes (0.84mg/kg). The vasodilation effect is short lived. Adenosine is contraindicated in patients with: Second or third degree atrioventricular (AV) block Sinus node disease, except for those with a functioning pacemaker Known or suspected bronchoconstrictive or bronchospastic lung disease Known hypersensitivity to adenosine 3. Dobutamine is administered IV, starting at 0.5-1.0 mcg/kg/min and titrated to reach the maximum heart rate for 2-5 minutes. The maximum dose is 40 mcg/kg/min. Atropine may be added in appropriate doses IV. Dobutamine is contraindicated in patients with: Idiopathic subaortic stenosis AMI Physician Supervision RequirementsMPI and blood pool imaging require general supervision by a qualified physician licensed to administer radioactive materials. Cardiology stress procedures performed in conjunction with nuclear MPI studies are covered by Medicare only when performed under the direct supervision of a qualified physician, who provides: Medical expertise required for performance of the test Medical treatment for complications and side effects of the test Medical services required as part of the test such as injections of medications Medical expertise in the interpretation of the cardiovascular stress test component, some of which has to be provided during the test and before the patient is discharged from the testing suite Summary of Evidence N/A Analysis of Evidence (Rationale for Determination) N/A

The 2 types of radionuclide studies commonly used for cardiac evaluation are myocardial perfusion imaging (MPI) and cardiac blood pool imaging (multiple gated acquisition scanning (MUGA), ventriculography). MPI is used primarily for the evaluation of coronary artery disease (CAD). Ventriculography is sometimes referred to as MUGA or cardiac blood pool imaging and is primarily used to evaluate valvular disease and cardiomyopathies. Either type of study may be obtained at rest or with stress. Stress may be provided by exercise or with pharmacologic agents. MPI is a diagnostic procedure that evaluates blood flow to cardiac muscle using radionuclides. A gamma camera is used to record images in planar or tomographic (single photon emission computed tomography (SPECT)) projections. Use of dual radiopharmaceuticals permit concurrent studies at rest and after stress, which are then compared and interpreted by a nuclear physician. Since the radiopharmaceutical accumulates in the myocardium in relation to blood flow, ischemic and infarcted myocardium can be detected. With the use of technetium based radiopharmaceuticals, the perfusion imaging may be linked to acquisition of “first pass” data to visualize blood flow through the right heart, lungs and left heart giving diagnostically useful information about cardiac chamber shunts, wall motion, cardiac output, ejection fraction (EF), left ventricular volume, shunt fraction and valvular regurgitation. Positron emission tomography (PET) scans performed for the diagnosis and management of patients with known or suspected CAD, using the Food and Drug Administration (FDA) approved Rubidium 82 (Rb 82) , are covered when the following conditions are met: The PET scan (at rest or rest with stress) is performed in place of SPECT; or Is performed following an inconclusive SPECT (results that are equivocal, technically uninterpretable, or discordant with the patient’s other clinical data). In such cases, the PET scan must have been determined to be medically necessary to guide further treatment of the patient. When a PET scan is performed as an additional diagnostic test in the instance of an equivocal SPECT, the reason for performing the PET scan must be clearly documented in the patient’s record. The following studies are considered investigational and will not be covered: Ambulatory radionuclide cardiac monitoring Monoclonal anti-myosin imaging Radionuclide imaging of thrombi Radionuclide imaging of cardiac adrenergic nerves Myocardial Perfusion Imaging Patients with a high pretest probability of disease are usually not candidates for this study unless determination of the size and reversibility of a defect are required for clinical decision making. Patients whose diagnosis is in question benefit most from this study. Patients with a low pretest probability of disease are usually not studied except when a prior exercise stress test by treadmill electrocardiogram (ECG) or echocardiogram (echo) is a presumed false positive. Stress MPI, preceded by satisfactory stress echo, is not medically necessary. Indications for Myocardial Perfusion Imaging 1. Acute myocardial infarction (AMI) - MPI is not typically performed during the acute period of myocardial infarction (MI), if the diagnosis is established by other means. In selected patients, imaging is appropriate in the assessment of: Disease severity Risk assessment and/or prognosis Efficacy of acute reperfusion therapy Evidence of myocardial salvage Suspected infarction when the combination of history and other tests is not diagnostic 2. Unstable angina - MPI may be useful as an adjunct to other tests in the diagnosis or treatment of unstable angina only when the combination of history and other tests is not diagnostic. In selected patients, imaging is appropriate for: Identification of ischemia in the distribution of a known lesion or in remote areas Identification of the severity/extent of disease in patients with medically unstable angina or ongoing ischemia Measurement of left ventricular function (LVF) 3. Chronic ischemic heart disease - The use of MPI is well established in the diagnosis and management of CAD and is covered in these situations: Diagnosis of CAD, especially in patients with atypical chest pain Evaluation of abnormal or suspected false positive stress ECG Evaluation of other symptoms suspicious for the diagnosis of CAD such as syncope and ventricular arrhythmia Assessment of myocardial viability after revascularization or medical management Planning percutaneous transluminal coronary angioplasty (PTCA) to identify lesions causing ischemia, if unknown Evaluation of suspected or known CAD prior to high risk surgical procedure Identification of the presence, location, extent, and severity of myocardial ischemia Assessment of drug therapy Assessment of symptoms suggesting restenosis following PTCA Assessment of symptoms suggesting ischemia following coronary artery bypass graft (CABG) Follow up of symptomatic ischemic heart disease 4. Congenital heart disease (CHD) - Echo is the method of choice for evaluating patients with known or suspected CHD. Selected patients may benefit from MPI when assessing for: Diagnosis of anomalies of the coronary circulation Kawasaki’s disease 5. Post-transplant cardiac disease Assessment of coronary arteriopathy Evaluation for ventricular dysfunction with post-transplant rejection Cardiac Blood Pool Imaging (MUGA, Ventriculography) These services are allowed for the evaluation of ventricular size, wall motion, stroke volume, and EF when this information is medically necessary to direct further evaluation and management of the cardiac condition. Indications for Cardiac Blood Pool Imaging (MUGA, Ventriculography) 1. Cardiomyopathy - Cardiac blood pool imaging (MUGA, ventriculography) is covered for: Diagnosis of hypertrophic cardiomyopathy and/or myocardial ischemia Differentiation of ischemic from non-ischemic cardiomyopathy 2. Post-transplant cardiac disease Assessment of coronary arteriopathy Evaluation for ventricular dysfunction with post-transplant rejection 3. Assessment of cardiac function for cardiotoxic chemotherapy A. One baseline study is considered medically necessary prior to the initiation of cardiotoxic chemotherapy when 1 of the following conditions is met: 1. No echo is planned or performed 2. Prior echo is uninterpretable due to poor visualization window B. Cardiac function monitoring during or at the completion of cardiotoxic chemotherapy. Cardiotoxic chemotherapy includes any of the following medications: · 5-FU (5 fluorouracil) · Adriamycin ® (doxorubicin) · Avastin ® (bevacizumab) · Cerubidine ® (daunorubicin) · Clolar ® (clofarabine) · Cytoxan ® (cyclophosphamide) · Epirubicin (Pharmorubicin ® ) · Gleevec ® (imatinib) · Herceptin ® (trastuzumab) · Ifex ® (ifosfamide) · Mutamycin ® (mitomycin) · Nexavar ® (sorafenib) · Novantrone ® (mitoxantrone) · Sutent ® (sunitinib) · Taxol ® (paclitaxel) · Taxotere ® (docetaxel) · Tykerb ® (lapatinib) · Valstar ® (valrubicin) · Xeloda ® (capecitabine) · Zavedos ® (idarubicin) Pharmacologic Stress Agents For those patients who are unable to reach 75-100% of their age predicted maximum heart rate by physiologic exercise, vasodilation can be achieved with the use of either dipyridamole or adenosine. Use of pharmacologic agents in MPI is not a standard of care and is not medically necessary unless exercise is not possible. In some cases dobutamine may be used to effect stress through its inotropic effect. 1. Dipyridamole is typically administered intravenously (IV) at 0.57 mg/kg over a 4-minute period. The maximum dose should not exceed 60 mg. Since the dilation effect persists, after injection of the radiopharmaceutical, its effect is typically reversed with IV aminophylline, which must be available to reverse ischemia when it occurs. Dipyridamole is relatively contraindicated in patients with: Known bronchospastic lung disease (asthma) Systemic hypotension (systolic blood pressure (BP) below 100 mm Hg.) AMI less than 48 hours old Unstable angina 2. Adenosine is administered IV at 0.14 mg/kg/min over 6 minutes (0.84mg/kg). The vasodilation effect is short lived. Adenosine is contraindicated in patients with: Second or third degree atrioventricular (AV) block Sinus node disease, except for those with a functioning pacemaker Known or suspected bronchoconstrictive or bronchospastic lung disease Known hypersensitivity to adenosine 3. Dobutamine is administered IV, starting at 0.5-1.0 mcg/kg/min and titrated to reach the maximum heart rate for 2-5 minutes. The maximum dose is 40 mcg/kg/min. Atropine may be added in appropriate doses IV. Dobutamine is contraindicated in patients with: Idiopathic subaortic stenosis AMI Physician Supervision Requirements MPI and blood pool imaging require general supervision by a qualified physician licensed to administer radioactive materials. Cardiology stress procedures performed in conjunction with nuclear MPI studies are covered by Medicare only when performed under the direct supervision of a qualified physician, who provides: Medical expertise required for performance of the test Medical treatment for complications and side effects of the test Medical services required as part of the test such as injections of medications Medical expertise in the interpretation of the cardiovascular stress test component, some of which has to be provided during the test and before the patient is discharged from the testing suite